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Background: Cost-effectiveness models for the treatment of long-term conditions often require 
information on survival beyond the period of available data.
Objectives: This paper aims to identify a robust and reliable method for the extrapolation 
of overall survival (OS) in patients with radioiodine-refractory differentiated thyroid cancer 
receiving lenvatinib or placebo.
Methods: Data from 392 patients (lenvatinib: 261, placebo: 131) from the SELECT trial are 
used over a 34-month period of follow-up. A previously published criterion-based approach is 
employed to ascertain credible estimates of OS beyond the trial data. Parametric models with and 
without a treatment covariate and piecewise models are used to extrapolate OS, and a holistic 
approach, where a series of statistical and visual tests are considered collectively, is taken in 
determining the most appropriate extrapolation model.
Results: A piecewise model, in which the Kaplan–Meier survivor function is used over the 
trial period and an extrapolated tail is based on the Exponential distribution, is identified as 
the optimal model.
Conclusion: In the absence of long-term survival estimates from clinical trials, survival esti-
mates often need to be extrapolated from the available data. The use of a systematic method 
based on a priori determined selection criteria provides a transparent approach and reduces the 
risk of bias. The extrapolated OS estimates will be used to investigate the potential long-term 
benefits of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer 
patients and populate future cost-effectiveness analyses.
Keywords: survival analysis, parametric extrapolation, piecewise models, decision criteria, 
radioiodine-refractory differentiated thyroid cancer
Introduction
The majority of patients with differentiated thyroid cancer (DTC) have a good prog-
nosis, with estimated 10-year survival rates of 92%.1 However, an estimated 5% of 
patients suffer from metastatic, radioiodine-refractory (RR) DTC,1–3 which is difficult 
to treat,4–6 associated with a high patient burden,7,8 and has a 10-year survival rate of 
only 10%.1 The goal of therapy for patients with RR-DTC is to delay disease progres-
sion and prolong survival.4,9
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Lenvatinib is a multiple receptor tyrosine kinase inhibitor 
that selectively inhibits multiple angiogenic and oncogenic 
signaling pathways10 and is indicated for the treatment of adult 
patients with progressive, locally advanced, or metastatic, dif-
ferentiated (papillary/follicular/Hürthle cell) RR-DTC.10 The 
key clinical evidence for lenvatinib is derived from a Phase III 
multicenter, double-blind, randomized (2:1), placebo-controlled 
trial (SELECT) comparing the efficacy and safety of lenva-
tinib and placebo in patients with progressive RR-DTC.11 The 
primary end point of SELECT was progression-free survival 
(PFS), with overall survival (OS) measured as a secondary end 
point. The trial was designed to allow patients randomized to 
the placebo group to receive optional open-label lenvatinib at 
the time of confirmed disease progression. Over the 34-month 
period of follow-up of the SELECT, lenvatinib was found to 
prolong PFS by almost 15 months compared with placebo 
(hazard ratio =0.21; 95% confidence interval [CI]: 0.14–0.31).11
While PFS is an important and significant measure of 
treatment success, OS is a key outcome for patients and 
health care providers. A high value is placed on OS by health 
technology assessment bodies, and it is a key component of 
 cost-effectiveness models for long-term conditions. However, 
benefits in OS often prove difficult to demonstrate, particularly 
due to the limited duration of clinical trials, whereas PFS clinical 
trial data are often more complete. Although PFS at 34 months 
of follow-up for the placebo and lenvatinib arms in SELECT 
was 0% and 33%, respectively, median OS was not reached in 
either treatment group, meaning that >50% of patients remained 
alive.12 Therefore, extrapolation of OS was considered more 
critical than that of PFS and is the focus of this manuscript.
Increasing trial time-horizons to capture reliable OS 
data would be prohibitively expensive, with results often 
not available for many years, thus delaying patient access to 
potentially beneficial new treatments. A method of obtaining 
estimates of long-term survival is by extrapolation from the 
available data. In cases where treatment effects on survival 
extend beyond the period investigated in clinical trials, 
extrapolation could reveal longer term treatment benefits that 
would have been missed by restricting the investigation to a 
shorter period.13 The purpose of this analysis is to identify 
the most appropriate extrapolation method for SELECT OS 
data in order to estimate the potential long-term benefit of 
lenvatinib in slowly evolving RR-DTC and for potential use 
in future cost-effectiveness evaluations.
Methods
The following sections describe the SELECT and the deriva-
tion of OS data, including the construction of Kaplan–Meier 
(KM) plots for adjusting OS data for potential bias due to 
the crossover design of the SELECT. These methods have 
been described in the previous literature14 and are important 
to the understanding of the current approach.
SELECT
The SELECT was a Phase III, randomized, double-blind, 
placebo-controlled, multicenter, crossover trial. Patients 
aged 18 years or older were eligible for enrollment and were 
recruited from the Americas, Europe, Asia, and Australia. 
In total, 392 patients were randomly assigned (block ran-
domization) in a 2:1 ratio to receive 24 mg once-daily oral 
lenvatinib (261 patients) or placebo (131 patients) in 28-day 
cycles. Trial follow-up was 34 months (cutoff point June 15, 
2014). Primary and secondary analyses were conducted in 
the intention-to-treat population.11
OS data from the SELECT – crossover correction 
and production of KM plots
Due to the crossover design of SELECT, where patients 
randomized to placebo were eligible to receive open-label 
lenvatinib on confirmed disease progression,11 87.8% of 
placebo-treated patients switched to lenvatinib. As a conse-
quence, although PFS data were unaffected by the crossover 
design of SELECT, OS survival for the placebo arm was 
biased, with placebo demonstrating a higher survival than 
what would have been observed without treatment switching 
due to the use of open-label lenvatinib. To adjust for this bias, 
a rank-preserving structural failure time (RPSFT) model was 
used.12,14 Table 1 shows the unadjusted and RPSFT-corrected 
median OS times for the lenvatinib and placebo arms of the 
SELECT. KM plots for both trial arms have been published 
by Schlumberger et al.11 In the current analysis, long-term 
OS is obtained by extrapolation from the RPSFT-corrected 
data over the trial period.
Table 1 Summary statistics of clinical trial data from SELECT, 
unadjusted and RPSFT corrected at 34 months of follow-up 
(June 15, 2014)
Lenvatinib Placebo
Deaths, n (%) 93 (35.6) 55 (42.0)
Unadjusted
 Median OS, months (95% CI) NE (30.9, NE) NE (21.7, NE)
 Unadjusted HR (95% CI) 0.80 (0.57, 1.12), nominal P=0.1993
RPSFT corrected
 Median OS, months (95% CI) NE (30.9, NE) 19.1 (14.3, NE)
 RPSFT-adjusted HR (95% CI) 0.53 (0.34, 0.82), nominal P=0.0051
Abbreviations: CI, confidence interval; HR, hazard ratio; NE, not estimable; OS, 
overall survival; RPSFT, rank-preserving structural failure time.
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Current analysis
Time-horizon
A 120-month (10-year) time-horizon was chosen in order to 
mitigate inherent uncertainty in the extrapolation of 34-month 
OS data over a lifetime-horizon. The 10-year time-horizon 
was deemed both sufficient to capture meaningful differences 
in OS and appropriate from an economic perspective since, 
according to published data, only 10% of patients with RR-
DCT survive at 10 years.1 The restricted mean, truncated at 
the 10-year time-horizon, was used to facilitate estimates of 
OS before and after the empirical data cutoff (at 34 months), 
while the extended mean was used to estimate CIs around the 
marginal OS difference. The uncertainty around the estimates 
was measured using the bootstrap method15 to evaluate the 
CIs. All statistical analyses were performed in STATA Version 
13 (StataCorp LP, College Station, TX, USA).
Selection of most appropriate extrapolation method
A peer-reviewed, five-criterion framework for the robust 
extrapolation of survival data (presented by Tremblay et al13) 
was applied to the RPSFT-adjusted SELECT data set in order 
to help identify the most plausible extrapolation for OS.
Criterion 1 – proportional treatment (PT) assumption testing: 
the PT assumption must be supported by the log-cumulative 
hazard plot (which would be parallel in the case of a PT effect) 
and the PT global test.16
Criterion 2 – extrapolated hazard function fitting in time and 
between trial arms: the hazard rates should have a similar 
time relation pattern between the extrapolation function and 
the KM survivor function. The characteristic of the relation 
between the hazard rates of both arms should be replicated by 
the modeling technique selected, for example, crossing lines 
would advocate a separate parametric model for each arm.
Criterion 3 – minimal Akaike information criterion (AIC) and 
Bayesian information criterion (BIC): for parametric models, 
the selected model must have a low AIC/BIC to demonstrate 
goodness-of-fit to the clinical data.
Criterion 4 – uncertainty in the results: uncertainty in 
model parameters should be considered when selecting the 
best model, as a high uncertainty would be a sign of low 
robustness.
Criterion 5 – similitude of pre-extrapolation marginal gain 
and realism of the extrapolated marginal gain: the realism 
of the marginal gain should be accounted for when selecting 
the best model as an unrealistic marginal gain would create 
bias in the economic analysis.
Although these five criteria provide a systematic approach 
for the identification of the model that most accurately 
extrapolates OS, they should be used as a theoretical guide 
only as it is often the case that not all of these criteria can be 
satisfied simultaneously when applied to real data.
Five model “classes” were considered for the extrapola-
tion of OS: PT models with a treatment covariate, acceler-
ated failure time (AFT) models with a treatment covariate, 
individual models (where the extrapolation for each arm is 
estimated separately, ie, no treatment covariate is used), KM 
survival function with parametric extrapolation, and Royston 
and Parmar spline technique. The Exponential, Weibull, 
Gompertz, Log-Normal, Log-Logistic, and Gamma distri-
butions were considered, where appropriate, in the model 
classes outlined earlier.
For the purposes of the current analysis, the selected 
extrapolation model needs to be compatible with a 10-year 
time-horizon. The Royston and Parmar technique is a flexible 
piecewise technique that uses segmental parameter partition-
ing.17 Although this allows for a better fit of the parametric 
function to the pre-34-month cutoff data, credibility for the 
tail extrapolation is lost. Therefore, the Royston and Parmar 
technique was deemed inappropriate for extrapolating data 
to 10 years in the current analysis. The models used in the 
current analysis were parametric (PT and AFT), individual 
(separate models for each arm of the SELECT), and piece-
wise (KM + extrapolated tail).
Results
Extrapolation of OS data from SELECT
Criterion 1 – PT assumption testing
PT assumption testing (Criterion 1) was performed by visual 
inspection of the log-cumulative hazard plot (Figure 1) and 
the PT global test (Schoenfeld residual test).18 The visual 
inspection revealed relatively straight but not parallel log-
cumulative plots. The PT global test yielded a P-value of 
0.7270, which did not indicate a significant deviation from 
the PT assumption. Due to the contradictory nature of the 
global test for a PT effect and the visual inspection of the 
log-cumulative hazard OS plot, the validity of the PT assump-
tion was ambiguous.
Criterion 2 – extrapolated hazard function fitting in time 
and between trial arms
A visual evaluation of the extrapolated hazard function fitting 
to the KM hazard function was performed. Inspection of the 
log-cumulative hazard plot (Figure 1) indicated that using fully 
parametric models with a treatment covariate (PT and AFT) 
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would, by definition, not adequately capture the crossing of 
hazards. Fitted and observed log-cumulative hazard functions 
were overlaid for both the PT (Figure S1) and individual mod-
els (Figure S2). Figure S1 shows that the Weibull (PT and AFT 
models) and Gamma (AFT model) have similar hazard patterns 
to the KM of empirical data after the plots have diverged. The 
fitting of individual models negates the PT assumption and may 
therefore better reflect the change in hazard at earlier points in 
time. The log-cumulative hazard plots for individual models 
(Figure S2) indicated that the Weibull, Gamma, and the Log-
Logistic distributions can be considered to have approximately 
similar hazard patterns to the KM of empirical data.
Criterion 3 – minimal AIC and BIC and Criterion 4 – 
uncertainty in the results
The difference in mean OS survival estimates between the 
lenvatinib and placebo arms of SELECT, summary statistics 
(based on the extended mean), CIs of the marginal difference, 
and AIC/BIC criteria are provided in Table 2 for models based 
on the PT assumption, individual models, and piecewise 
models. The different classes display similar findings in terms 
of ranking the best fitted models to the empirical data. The 
Log-Logistic, Gompertz, Gamma, and Log-Normal extrapo-
lations are ranked third, fourth, fifth, and sixth, respectively, in 
each of the model classes when evaluating the AIC statistics. 
This result is closely matched in the BIC statistics; however, 
in each class, the Log-Normal extrapolation is ranked fifth 
and the Gamma sixth. In the case of the individual models, 
Figure 1 Log-cumulative hazard plot for OS.
Abbreviation: OS, overall survival.
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Table 2 Difference in mean OS estimates between the lenvatinib and placebo arms and associated information criteria for each fitted 
model
Empirical data Difference CI−a CI+a AIC BIC
KM 6.07 2.27 9.87 NA NA
Extrapolations Difference CI− CI+ AIC BIC
Plots are parallel – PT models
 Weibull 20.72 9.69 31.74 728.61 740.38
 Log-Normal 48.88 5.82 91.95 732.93 744.7
 Log-Logistic 65.92 5.33 126.52 729.18 740.95
 Exponential 22.99 8.7 37.29 728.88 736.73
 Gamma 21.76 6.33 37.19 730.56 746.25
 Gompertz 14.54 6.47 22.59 729.81 741.58
Plots are not parallel – individual models
 Weibull 27.66 11.58 43.74 729.20 741.92
 Log-Normal 102.74 0.04 205.44 733.35 746.07
 Log-Logistic 169.45
−95.26 434.17 729.44 742.15
 Exponential 23.00 8.70 37.29 728.88 735.23
 Gamma 22.34
−26.85 71.52 732.83 751.90
 Gompertz 16.58 7.30 25.85 731.25 743.96
Plots are not straight lines – piecewise models
 Weibull 15.20 8.00 21.21 728.61b 740.38b
 Log-Normal 13.61 6.64 19.28 732.93b 744.70b
 Log-Logistic 13.11 5.12 19.78 729.18b 740.95b
 Exponential 15.58 8.22 21.71 728.88b 736.73b
 Gamma 15.19 7.59 21.50 730.56b 746.25b
 Gompertz 12.48 7.08 17.29 729.81b 741.58b
Notes: aExtended means were used for the CIs and point estimates except for piecewise models, where restricted mean at 120 months was used. bAIC/BIC – as no AIC/BIC 
data are available for this type of piecewise model, the AIC/BIC of the parametric function used for the tail extrapolation is presented as a proxy.
Abbreviations: AIC, Akaike information criterion; BIC, Bayesian information criterion; CI, confidence interval; KM, Kaplan–Meier; NA, not applicable; OS, overall survival; 
PT, proportional treatment.
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the Exponential extrapolation would be ranked first from 
the perspective of both the AIC and the BIC. This ranking 
is repeated in the BIC results for the PT models; however, 
the AIC statistics show the Weibull to be a better fit than 
the Exponential. The CIs do not go below 0 for any of the 
extrapolations in the PT and piecewise model classes. In the 
individual model class, both the Log-Logistic and Gamma 
extrapolations have lower bounds crossing 0. In each of the 
model classes, the Log-Normal and Log-Logistic extrapola-
tions exhibit the highest levels of uncertainty (widest CIs).
Criterion 5 – similitude of pre-extrapolation marginal gain 
and realism of the extrapolated marginal gain
Criterion 5 is a “rule of thumb” designed to evaluate the 
robustness of the marginal survival gain of the extrapolation 
in comparison with that shown in the pre-extrapolation KM. 
The marginal survival gain prior or post the trial cutoff is 
divided by the time prior or post the trial cutoff, respectively. 
The resulting ratio in the post-trial period should be equal or 
inferior to the ratio in the pre-extrapolation period, that is, 
if the ratio is much higher after the cutoff, it suggests that 
the marginal gain is exaggerated in the post-cutoff period 
(resulting in a “long” and/or “thick” tail). The ratios that serve 
as the basis for evaluating Criterion 5 are shown in Table 3.
Of the PT models, the Log-Normal, Log-Logistic, and 
Gompertz distributions satisfied Criterion 5 in terms of the 
comparison of the KM rate of survival gain against the post-
extrapolation rate of survival gain. However, of these, only 
the Log-Normal distribution satisfied Criterion 5 in terms 
of comparison between the pre- and post-extrapolation rate 
of gain. The Weibull and Gamma distributions both satisfied 
Criterion 5 in terms of the comparison between pre- and 
post-extrapolation rate of gain; however, in both instances, 
the extrapolated rate of gain in the pre-extrapolation period 
was greater than the KM rate of survival gain.
All the individual models failed to satisfy Criterion 5 
in terms of the comparison of the KM rate of survival gain 
against the post-extrapolation rate of survival gain. The 
Weibull, Exponential, Gamma, and Gompertz distributions 
all satisfied the criterion in terms of the comparison between 
pre- and postextrapolated rate of survival gain. Neither the 
Log-Normal nor the Log-Logistic distributions satisfied 
the criterion when either the KM or pre-extrapolation rate 
was compared against the postextrapolation rate. For both 
distributions, the postextrapolation rate of survival gain is 
noticeably higher than the KM rate of survival gain, a result 
indicative of both distributions being characterized by “long” 
tails. Using the KM survival function with extrapolated tail, 
all evaluated distributions satisfied Criterion 5.
The individual results for the application of each of the five 
criteria in the model selection framework are presented in Table 4.
Extrapolation using the most appropriate model
The results indicate that a piecewise model appears to be the 
most appropriate for extrapolating the RPSFT-adjusted OS 
trial data. Deviance under the PT assumption is inconsistent, 
and data are unfavorable for Log-Normal and Log-Logistic 
distributions in all the evaluated model types.
The best fitting functional forms (in descending order 
of fit) were:
1. Piecewise model: Exponential tail, Weibull tail, Gompertz 
tail, Gamma tail
2. Parametric model: Exponential (PT model), Weibull (PT 
model), Gompertz (PT model), Gamma (AFT model)
3. Individual model: Exponential, Weibull, Gompertz, 
Gamma
Figure 2 presents the extrapolation of the RPSFT-adjusted 
OS trial data, using the most appropriate model according 
to the results: a piecewise model: KM + an exponentially 
extrapolated tail.
Table 5 presents the summary statistics of pre- and post-
cutoff OS using the restricted (120-month, 10-year) time-
horizon. Of the three exponential model types (PT,  individual, 
Table 3 Evaluation of Criterion 5 – estimated rate of survival gain per month by receiving lenvatinib instead of placebo, before and 
after the trial cutoff
KM Weibull Log-Normal Log-Logistic Exponential Gamma Gompertz
PT models Pre-extrapolation 0.13 0.18 0.10 0.14 0.15 0.17 0.17
Extrapolated tail 0.15 0.11 0.13 0.15 0.15 0.11
Individual models Pre-extrapolation 0.13 0.21 0.14 0.18 0.15 0.19 0.20
Post-extrapolation 0.20 0.19 0.21 0.15 0.16 0.17
Piecewise models Pre-extrapolation 0.13 0.13 0.13 0.13 0.13 0.13 0.13
Post-extrapolation 0.12 0.11 0.10 0.13 0.12 0.09
Notes: The rate of survival gain in the pre-extrapolation period is defined as the difference in survival between lenvatinib and placebo at 36 months divided by the number 
of months in the pre-extrapolation period (ie 36 months). The rate of survival gain in the post-extrapolation period is defined as the marginal relative difference in the 
extrapolated period (post cut-off) divided by the number of months post-cut-off. 
Abbreviations: KM, Kaplan–Meier; PT, proportional treatment.
ClinicoEconomics and Outcomes Research 2016:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
328
Tremblay et al
and KM + extrapolated tail), the KM + extrapolated tail 
provides the most conservative extrapolation estimate.
The total OS difference between lenvatinib and placebo 
ranged from 12.48 months to 15.58 months using the KM 
+ extrapolated tail. The largest marginal survival gain was 
observed with an Exponential tail (15.58 months for lenva-
tinib) and the smallest with a Gompertz tail (12.48 months). 
The largest estimates of OS for both lenvatinib and placebo 
were provided by Log-Normal (53.86 and 40.25, respectively) 
and Log-Logistic tails (50.85 and 37.74 months, respec-
tively). This further reinforced the judgment that distributions 
characterized with a long tail were unsuitable for extrapolat-
ing OS data in this context. The KM + Exponential and KM + 
Weibull extrapolations (the first and second best fitting forms) 
provided similar OS estimates with a 0.38-month difference 
between these extrapolations for total OS gain.
Table 4 Evaluation of all the five criteria in the model selection framework for the extrapolation of survival data
Model class Weibull Log-Normal Log-Logistic Exponential Gamma Gompertz
PT models C1 – PT assumption Mixed evidence on the deviance. Lines are not parallel and are not straight, but the PT global test does 
not show a deviance
C2 – hazard fitting    
C3 – AIC First Sixth Third Second Fifth Fourth
C3 – BIC Second Fifth Third First Sixth Fourth
C4 – uncertainty    
C5 – thumb rule     
Individual models C1 – PT assumption Lines are not straight and one convergent segment is followed by a divergent segment in the log-
cumulative hazard plot, which could generate a crossing in the individual parametric curves. This 
crossing would not be suggested by the data
C2 – hazard fitting    
C3 – AIC Second Sixth Third First Fifth Fourth
C3 – BIC Second Fifth Third First Sixth Fourth
C4 – uncertainty   
C5 – thumb rule    
Piecewise models C1 – PT assumption Piecewise models are particularly relevant to this context, as the log-cumulative hazard plots seem not 
straight and not parallel
C2 – hazard fitting    
C3 – AIC First Sixth Third Second Fifth Fourth
C3 – BIC Second Fifth Third First Sixth Fourth
C4 – uncertainty      
C5 – thumb rule      
Abbreviations: AIC, Akaike information criterion; BIC, Bayesian information criterion; PT, proportional treatment.
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Figure 2 OS extrapolation result, using a piecewise model.
Abbreviation: OS, overall survival.
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Using the KM + exponentially extrapolated tail, the 
benefit associated with lenvatinib, relative to placebo, was 
4.45 months pre-extrapolation and estimated at 11.13 months 
postextrapolation – giving a total OS benefit of 15.58 months 
with lenvatinib treatment over the 120-month (10-year) 
time-horizon.
Discussion
OS is a key outcome in determining the efficacy of cancer thera-
pies in clinical trial settings.19 An OS benefit can be difficult to 
demonstrate due to the limited duration of clinical trials and 
the potential confounding due to subsequent treatments that 
patients may receive.11 This was the case in the SELECT, in 
which ~50% of patients remained alive at the 34-month data 
cutoff point, and 87.8% of patients originally randomized to 
receive placebo had switched over to lenvatinib following docu-
mented disease progression. The purpose of this analysis was 
to extrapolate OS data from the SELECT, in order to estimate 
the potential long-term benefits of lenvatinib for use in future 
cost-effectiveness evaluations. Our work is novel in that it uses 
a holistic approach in the selection of the most appropriate 
model for the long-term extrapolation of survival when a high 
percentage of individuals are still alive at the end of follow-up.
The extrapolation of OS data used an RPSFT model to cor-
rect for potential confounding due to crossover14 and  followed 
a previously published, systematic method to determine the 
most suitable approach to extrapolate OS data.13 The use of this 
systematic method (involving five criteria)13 was considered a 
strength of this analysis. Testing of Criterion 1 regarding the 
PT assumption was inconclusive as the log-cumulative hazard 
OS plots from SELECT were relatively straight but not paral-
lel, while the global test for a PT effect was not significant. 
While some researchers would not consider the evidence 
regarding the use of the PT assumption to be prohibitive, it 
is the opinion of the authors that, if using a PT assumption, 
proof should be presented that individual models and piece-
wise models (such as the KM model + extrapolated tail) are 
inferior. Piecewise models use the observed hazard from the 
clinical trial data by applying the KM survivor estimator over 
the trial period; thus, they can be superior to parametric mod-
els and individual models when their underlying assumptions 
are inappropriate. Therefore, a piecewise model (ie, KM + 
extrapolated tail) appeared to be a suitable alternative.
A potential limitation of this analysis is that OS for the 
placebo arm of the SELECT was obtained by fitting an 
RPSFT model. Although this approach can be used to correct 
for potential confounding due to the crossover design of the 
SELECT, a key assumption in RPSFT models is that the treat-
ment is acting by multiplying survival time by a given factor 
once patients start receiving active treatment. Therefore, OS 
Table 5 Summary statistics of pre- and post-cutoff OS (120-month time-horizon) – survival difference (months)
Weibull Log-Normal Log-Logistic
Lenv Pl Diff Lenv Pl Diff Lenv Pl Diff
KM Pre-extrapolation 24.83 20.38 4.45 24.83 20.38 4.45 24.83 20.38 4.45
Parametric models Pre-extrapolation 24.88 18.91 5.97 24.73 21.20 3.53 24.88 20.03 4.85
Post-extrapolation 17.81 4.99 12.82 29.83 20.64 9.20 25.81 14.98 10.83
Total 42.69 23.90 18.79 54.56 41.84 12.72 50.69 35.01 15.68
Individuals Pre-extrapolation 24.82 17.81 7.01 24.81 20.05 4.76 24.87 18.79 6.08
Post-extrapolation 19.73 2.32 17.41 31.45 14.73 16.71 27.53 9.88 17.64
Total 44.55 20.13 24.42 56.26 34.78 21.48 52.40 28.68 23.72
KM tail Pre-extrapolation 24.83 20.38 4.45 24.83 20.38 4.45 24.83 20.38 4.45
Post-extrapolation 18.63 7.89 10.74 29.03 19.87 9.16 26.02 17.36 8.66
Total 43.46 28.26 15.20 53.86 40.25 13.61 50.85 37.74 13.11
Exponential Gamma Gompertz
Lenv Pl Diff Lenv Pl Diff Lenv Pl Diff
KM Pre-extrapolation 24.83 20.38 4.45 24.83 20.38 4.45 24.83 20.38 4.45
Parametric models Pre-extrapolation 24.76 19.77 4.99 24.86 19.16 5.70 24.82 19.09 5.73
Post-extrapolation 21.80 8.53 13.27 19.23 6.30 12.94 13.50 4.03 9.48
Total 46.56 28.30 18.26 44.10 25.46 18.64 38.33 23.12 15.21
Individuals Pre-extrapolation 24.76 19.77 4.99 24.82 18.48 6.34 24.81 17.91 6.89
Post-extrapolation 21.80 8.53 13.27 18.81 5.01 13.80 15.64 1.19 14.45
Total 46.56 28.30 18.26 43.63 23.49 20.14 40.44 19.10 21.34
KM tail Pre-extrapolation 24.83 20.38 4.45 24.83 20.38 4.45 24.83 20.38 4.45
Post-extrapolation 21.95 10.83 11.13 19.96 9.23 10.73 14.32 6.29 8.03
Total 46.79 31.21 15.58 44.80 29.61 15.19 39.15 26.67 12.48
Abbreviations: Diff, difference; KM, Kaplan–Meier; Lenv, lenvatinib; OS, overall survival; Pl, placebo.
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during the trial period was obtained by making use of the PT 
assumption; thus, rejecting the PT assumption on the grounds 
of the results of Criterion 1 alone may be inappropriate and 
inconsistent with the overall approach. If overall consistency 
were to be used as an additional criterion to select the most 
appropriate extrapolation technique, PT models should be 
considered as a legitimate option.
The AIC/BIC statistics support the use of the Exponential 
distribution in all cases, but it should be noted that the use of 
the AIC alone would have identified the Weibull distribution 
as the best fit to the empirical data under the PT assump-
tion. Furthermore, as the AIC and BIC are not available for 
piecewise models, they are estimated via the fitting of the full 
parametric distributions, which are used as a proxy for the tail 
of the extrapolation. AIC and BIC only reflect a distribution’s 
goodness-of-fit in the presence of empirical data; they do 
not provide information regarding the appropriateness of the 
extrapolation. Log-Normal and Log-Logistic curves, irrespec-
tive of their AIC/BIC, were excluded a priori under Criterion 
3, due to the high risk of a long tail. The ranking of models and 
distributions was confirmed under the remaining criteria (4 
and 5). There is very little difference between the AIC statistics 
for the first three best “fitting” distributions. Consideration 
as to which distribution provides the best extrapolation of 
the data, using the AIC in isolation could lead to an analyst 
choosing the Log-Logistic. However, the results of Criterion 
5 would suggest that the use of the Log-Logistic distribution 
could lead to an unrealistic marginal gain in mean survival.
The consideration of all five criteria offers a more holistic 
approach in the selection of the most appropriate model. 
The analysis determined that a piecewise model was the 
most suitable for extrapolation of the SELECT OS data. The 
framework used in the current analysis should be considered 
as an informed guide to model selection, rather than defini-
tive. Had judgments been based solely on a statistical test 
of proportionality or the commonly used AIC, a different 
decision would have been made regarding the appropriate 
extrapolation of OS data from SELECT.
RR-DTC is a chronic condition, requiring long-term 
data for the robust assessment of benefits of treatment. With 
longer time-horizons, however, extrapolations are subject 
to increased uncertainties, such as the potential bias in the 
expectation of the survival gain. Therefore, a 10-year horizon 
was chosen in an attempt to balance the uncertainty inherent 
in any extrapolation (unacceptably high uncertainties as with 
a lifetime extrapolation), and the need to reflect all relevant 
differences in benefit (in contrast to the raw trial data alone).
The extrapolation of OS data from SELECT could be 
valuable in both clinical and economic analyses comparing 
lenvatinib with other treatments for RR-DTC in the future.
Conclusion
In order to fully capture the benefits of a therapy, it is often 
necessary to extrapolate survival data to a sufficient time 
point. The use of a transparent, systematic approach with an 
a priori selection process is required to facilitate the choice 
of an extrapolation method while reducing the risk of bias. 
Although it is tempting to present an extrapolation method 
that demonstrates the greatest marginal benefits, an appropri-
ate approach should be conservative and fulfill the selection 
criteria. For the extrapolation of the RPSFT-adjusted OS data 
in SELECT, a piecewise model was considered the optimal, 
where the KM survivor function was used for the period of 
the trial data and the extrapolated tail was modeled using an 
Exponential distribution. The results presented here should 
not be considered definitive and should be used alongside 
expert clinical opinion to inform a final decision; nonetheless, 
they offer a valuable insight into extrapolation approaches 
for future comparative analyses.
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Figure S1 Log-cumulative hazard plots for OS comparing observed (KM) with fitted estimates obtained from PT models.
Abbreviations: KM, Kaplan–Meier; OS, overall survival; PT, proportional treatment.
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Figure S2 Log-cumulative hazard plots for OS comparing observed (KM) with fitted estimates obtained from individual models.
Abbreviations: KM, Kaplan–Meier; OS, overall survival.
